We hold pharmaceutical companies responsible for drug-induced illness.


Wonder drug among blood thinners or bad medicine?

Xarelto® (rivaroxaban) is advertised as a wonder drug — a “next generation” blood thinner to replace warfarin for prevention of blood clots and stroke. Unfortunately, Xarelto’s makers chose not to warn that the drug also causes uncontrollable internal bleeding that may lead to death. That calculated decision has led to hundreds of deaths and many more injuries.

Xarelto is a new type of anticoagulant, or blood thinner, known as a “Factor Xa inhibitor.” The drug “inhibits,” or prevents, blood clots from forming.

The U.S. Food and Drug Administration (FDA) has approved Xarelto for a number of specified uses, including:

  • For hip and knee replacement patients, to avoid and treat deep vein thrombosis (DVT) and pulmonary embolism (PE); and
  • For nonvalvular atrial fibrillation (NVAF) patients, to minimize the risk for stroke.

Before Xarelto and other blood thinners like it came on the market, doctors prescribed warfarin (Coumadin) or heparin. The problem with warfarin is that users must take the drug at mealtime, eat a limited diet and have their blood monitored frequently. These restrictions are unnecessary with Xarelto, its manufacturers claim.

But these are not the only differences between Xarelto and warfarin. With Xarelto, once internal bleeding starts — even from something simple like banging your shin on the bed corner — there is no way to stop it. With warfarin, by contrast, internal hemorrhaging can be controlled with high doses of vitamin K or plasma products.

Xarelto lawsuits filed across the country describe a variety of injuries caused by Xarelto’s dangerous side effects.

Xarelto: uncontrollable bleeding. The risk of unstoppable, possibly fatal, bleeding is Xarelto’s most dangerous side effect. Symptoms of internal hemorrhaging include: headaches, spitting up blood, and a stool that is red or black. The risk for injury is even higher when Xarelto is consumed with other drugs, including aspirin and several others.

Xarelto: wound complications. Patients who undergo knee or hip replacement surgery sometimes receive Xarelto to reduce the risk of deep vein thrombosis and pulmonary embolism. But a number of studies indicate that patients given other treatments, like compression stockings and aspirin, actually have fewer wound complications than those treated with Xarelto. Post-surgical complications with Xarelto include:

  • Excessive oozing and drainage;
  • Rupture;
  • Infection;
  • Hematoma;
  • Chronic pain in the surgical site;
  • Limited range of motion; and
  • Revision surgery to correct the Xarelto-related wound complications.

Xarelto: Blood clots near the spinal cord. Patients taking Xarelto may be at risk for developing a blood clot around the spinal cord or in the brain when undergoing a spinal tap or receiving an epidural anesthetic. Such blood clots may cause stroke, paralysis and other injuries. Xarelto patients at a heightened risk include those who:

  • Need an epidural catheter to administer medication through the back;
  • Use non-steroidal anti-inflammatory drugs (NSAIDs);
  • Have had difficulty with previous spinal punctures or had them frequently; and
  • Have undergone spinal surgery.

Xarelto: Other side effects. Here are some other commonly reported Xarelto side effects. Some are potentially life threatening:

  • Dramatic changes in blood pressure;
  • Racing heartbeat (tachycardia);
  • Irregular heartbeat (arrhythmia);
  • Diarrhea;
  • Numbness and itching, tingling or burning of the skin;
  • Bladder or gastrointestinal problems;
  • Difficulty swallowing;
  • Headaches;
  • Dizziness or fainting;
  • Back pain;
  • Weakness or pain in the extremities; and
  • Muscle spasms.

Xarelto is manufactured by the German pharmaceutical giant, Bayer A.G. The anticoagulant is marketed by the Belgian company, Janssen Pharmaceutical, which has been a division of Johnson & Johnson since 1961.

Though Xarelto’s manufacturers knew of the drug’s potentially dangerous side effects, the companies chose not to share their knowledge.

This is not the first time these mega-pharmaceutical firms have hidden their products’ dangers from the American public. And in 2012, Waters Kraus & Paul worked with the State of Texas to settle civil and criminal charges that Janssen and Johnson & Johnson paid kickbacks to pharmacists and marketed their Risperdal drug without FDA approval for uses that put children and the elderly at risk for serious harm.

Contact Waters Kraus & Paul to file a Xarelto lawsuit

With a national presence and a wealth of experience representing clients injured by dangerous products and unsafe medical devices, Waters Kraus & Paul as your Xarelto lawyer provides aggressive representation throughout the entire course of litigation.

To learn more about legal representation at Waters Kraus & Paul, or to have one of our attorneys review your potential Xarelto lawsuit, email us or call 800.226.9880.

Xarelto Facts at a Glance
  • New type of blood thinner
  • Used to prevent blood clots and stroke
  • Can Cause uncontrollable internal bleeding
  • No means to stop severe bleeding
  • 2012: 151 Xarelto death reports
  • 2013: 593 Xarelto bleeding reports
Dangerous Xarelto Drug Combinations
  • Aspirin
  • Coumadin, Jantoven (warfarin)
  • Heparin
  • Nplate (romiplostim)
  • Plavix (clopidogrel)
  • Priftin (rifapentine)
  • Rifadin, Rifater or Rifamate (rifampin)
  • St. John’s wort
  • Vaprisol (conivaptan)

Xarelto vs. Aspirin…The Outcome May Shock You

January 2, 2018 According to a study, prescription Xarelto® shows no superiority compared to over-the-counter aspirin. Bayer and Johnson & Johnson’s Janssen Research & Development have acknowledged that their Xarelto® (rivaroxaban) has failed a Phase III trial assessing the anticoagulant in patients with…

Xarelto Dangers Investigated in Canada

October 12, 2015 The Canadian government has recently initiated a probe into the dangers associated with the blood thinner Xarelto (rivaroxaban). In July 2011, the U.S. Food & Drug Administration (FDA) approved the anti-clotting agent for patients receiving knee and hip replacements, to…

Gary Paul, Michael Armitage & Scott Frost Named on 2018 Southern California Super Lawyers List

February 13, 2018 Waters Kraus & Paul partners selected to appear in 2018 Southern California Super Lawyers Magazine Gary Paul, Michael Armitage, and Scott Frost, partners at Waters Kraus & Paul, have each respectively been selected for inclusion in the 2018 Southern California Super Lawyers list as featured in special sections of The New York Times and The Los Angeles Magazine. This is a special honor in that the list is comprised of only five percent of attorneys in Southern California. About Southern California Super Lawyers Super Lawyers® is a publication of Thompson Reuters and uses a patented multi-phase process to recognize only…
Waters Kraus & Paul attorneys included in Super Lawyers List 2018

What are my chances?

That’s the first question everyone asks. The truth is it’s impossible to know. But we can tell you this. Waters Kraus & Paul has what it takes to fight against big corporate interests and win. That’s why we’ve taken more mesothelioma trials to verdict than any other firm. And that’s why we’ve recovered more than $1.3 billion for clients like you. Do you think you have a case? Contact us now to speak with an attorney.

Call 800.226.9880